news
Empagliflozin trial halted after successful outcome in chronic kidney disease
An early halt has been called to a major kidney drug trial following positive results for patients with chronic kidney disease (CKD).
List view / Grid view
Empagliflozin
news
Empagliflozin benefits adults hospitalised for acute heart failure, shows study
Phase III trial shows that adults hospitalised for acute heart failure were 36 percent more likely to experience a clinical benefit if initiated on empagliflozin.
news
FDA hands Boehringer and Lilly complete response letter for insulin adjunct
Boehringer Ingelheim and Eli Lilly have received a complete response letter from the US FDA for their sNDA of empagliflozin 2.5mg, an insulin adjunct.
news
FDA approves label update to sodium glucose co-transporter-2 (SGLT2) inhibitors
Safety updates to labels of SGLT2 inhibitors will recommend temporary discontinuation of these medications before scheduled surgery, says the FDA.
news
Diabetes drug trial needs to widen participants to understand full impact
More work needs to be done to examine the real world effects of the commonly prescribed diabetes drug empagliflozin, new research finds...
news
New data from Boehringer Ingelheim and Lilly showcase strength of Diabetes Alliance
25 September 2012 | By Boehringer Ingelheim / Eli Lilly & Company
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) will present data for three molecules, including two investigational compounds, from their Diabetes Alliance portfolio at the 48th European Association for the Study of Diabetes (EASD) Annual Meeting in Berlin, 1–5 October 2012. Now in its second year, the Boehringer-Lilly Alliance…
